Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.58 |
| ▸ | MMP9 | P14780 | 5/20 | 0.58 |
| ▸ | MMP8 | P22894 | 5/20 | 0.58 |
| ▸ | MMP13 | P45452 | 5/20 | 0.58 |
| ▸ | COMT | P21964 | 1/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.51 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5306882 | 0.95 | MMP2 (0.66) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL13696438 | 0.90 | MAPT (0.57) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL1136397 | 0.88 | NR2E3 (0.61) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL1136378 | 0.88 | MMP2 (0.53) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL2988212 | 0.88 | KIT (0.47) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL13696439 | 0.86 | MMP2 (0.59) | MMP2MMP9MMP8MMP13KMT2A | |
| SCHEMBL5306883 | 0.85 | MMP2 (0.56) | MMP2MMP9MMP8MMP13COMT | |
| SCHEMBL4481981 | 0.84 | ABL1 (0.58) | MMP2MMP9MMP8MMP13KDR | |
| SCHEMBL4472721 | 0.84 | NR2E3 (0.59) | KDRNR2E3 | |
| SCHEMBL1136409 | 0.84 | BLK (0.57) | MMP2MMP9MMP8MMP13COMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618964-B2 | Benzamide derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | claimed |
| CN-101087787-A | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | claimed |
| EP-1833829-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | claimed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | claimed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| EP-2872161-B1 | DIANHYDROGALACTITOL FOR USE IN TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS | DEL MAR PHARMACEUTICALS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-7618964-B2 | Benzamide derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-14 | — | — | US | disclosed |
| CN-101087787-A | Heterocyclic carbamate derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2007-12-12 | — | — | CN | disclosed |
| EP-1833829-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYRROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006066913-A2 | BENZAMIDE SUBSTITUTED IMIDAZO- AND PYROLO-PYRIDINES AS PROTEIN KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | MMP2 4831/4885MMP9 4877/4885MMP8 4684/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | MMP2 4793/4885MMP9 4876/4885MMP8 4668/4885 |
| US-20080039460-A1 | Benzamide Derivatives, Their Manufacture and Use as Pharmaceutical Agents | TMBIM6, BAK1, CYP3A5 | MMP2 2405/4885MMP9 2279/4885MMP8 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.